Metabolic Causes of Hypoglycemia and Seizures in Newborns/Infants
Beyond hyperinsulinemic hypoglycemia, the key metabolic disorders causing hypoglycemia and seizures in newborns and infants include glycogen storage diseases (particularly Type I and III), fatty acid β-oxidation disorders, and ketotic hypoglycemia, with these conditions accounting for a substantial proportion of persistent or recurrent hypoglycemic seizures in this age group 1, 2.
Primary Metabolic Etiologies
The most clinically significant metabolic causes are:
Glycogen Storage Disorders
- Glycogen Storage Disease Type I (GSD I): Most severe form causing profound hypoglycemia
- Glycogen Storage Disease Type III (GSD III): Presents with hypoglycemia particularly during childhood, though less severe than Type I 3, 2
- These disorders impair hepatic glucose production through enzymatic defects in glycogen breakdown
Fatty Acid β-Oxidation Disorders
- Prevent mobilization of alternative fuels during fasting
- Result in hypoketotic hypoglycemia (critical distinguishing feature)
- Include disorders like MCAD, VLCAD, and LCHAD deficiencies 2
Ketotic Hypoglycemia
- Most common cause in the post-neonatal infant-child group after hyperinsulinism
- Due to abnormalities in substrate availability
- Typically presents after age 18 months 4, 5
Clinical Presentation and Seizure Characteristics
Hypoglycemic seizures from metabolic causes present differently based on timing and severity 2:
- Brief seizures (68% of cases): More common, typically clonic or tonic-clonic
- Status epilepticus (32% of cases): Occurs earlier (mean 1.4 days in neonates vs 4.3 days for brief seizures, p=0.02)
- Recurrent status epilepticus often triggered by fever following initial episode
- Critical finding: 21% of patients with hypoglycemic seizures develop epilepsy, with shorter delay when grey matter lesions present (1.9 months) versus white matter damage (3.3 years, p=0.003) 2
Diagnostic Approach
The critical samples ("critical blood draw") must be obtained during hypoglycemia before treatment 1, 6:
Essential Laboratory Tests During Hypoglycemia:
- Glucose level (confirm <50 mg/dL in neonates, <60 mg/dL in infants)
- Insulin and C-peptide (to exclude hyperinsulinism)
- Ketones (beta-hydroxybutyrate): Absent/low in fatty acid oxidation defects and hyperinsulinism; present in ketotic hypoglycemia
- Free fatty acids: Elevated in ketotic hypoglycemia, low in hyperinsulinism
- Lactate and pyruvate: Elevated in GSD Type I
- Acylcarnitine profile: Abnormal in fatty acid oxidation disorders
- Urine organic acids: Diagnostic for specific metabolic disorders
Additional Workup:
- Ammonia: May be elevated in fatty acid oxidation defects
- Liver function tests: Hepatomegaly common in GSD
- Cortisol and growth hormone: Exclude endocrine causes
Management Priorities
Immediate glucose correction is paramount to prevent irreversible neurological injury, but the specific long-term management depends on the underlying metabolic disorder 1, 6:
Acute Management:
- IV dextrose bolus (2 mL/kg of D10W or 0.2 g/kg)
- Continuous glucose infusion to maintain normoglycemia
- Avoid rapid glucose spikes: Associated with poorer neurodevelopmental outcomes 7
Disorder-Specific Chronic Management:
GSD Type I:
- Frequent feeds with complex carbohydrates
- Uncooked cornstarch (provides sustained glucose release)
- Avoid fasting >3-4 hours
- Continuous overnight gastric drip feeding may be necessary 3
GSD Type III:
- High-protein diet (protein provides gluconeogenic substrates)
- Cornstarch supplementation
- Avoid prolonged fasting
- Caution: Statins contraindicated due to myopathy risk 3
Fatty Acid Oxidation Disorders:
- Avoid fasting (critical trigger)
- High-carbohydrate, low-fat diet
- Medium-chain triglyceride (MCT) oil supplementation for some disorders
- L-carnitine supplementation
- Emergency protocol for illness (prevent catabolism)
Ketotic Hypoglycemia:
- Frequent meals with complex carbohydrates
- Bedtime snack essential
- Usually resolves by age 8-9 years
Critical Pitfalls to Avoid
Diagnostic Errors:
- Missing the critical blood draw: Samples must be obtained BEFORE glucose administration or diagnosis may be impossible 6
- Assuming all neonatal hypoglycemia is transient: 340 inherited metabolic disorders can cause hypoglycemia 1
- Relying solely on Expanded Newborn Screening: Many metabolic causes (Molybdenum-Cofactor Deficiency, Hypophosphatasia, GLUT1-Deficiency) are NOT detected by standard screening 6
Treatment Errors:
- Treating seizures with antiepileptic drugs alone: Worse neurological outcomes occur when underlying metabolic disease not addressed with specific treatment 6
- Using beta-blockers in GSD III with cardiomyopathy: Masks hypoglycemia symptoms 3
- Rapid IV dextrose boluses: Associated with poorer neurodevelopmental outcomes; prefer controlled infusions 7
Prognosis and Long-term Considerations
Severe and prolonged hypoglycemia causes irreversible neurological injury with documented impairments in visual-motor processing, executive functioning, and academic performance 7. The risk of developing epilepsy after hypoglycemic status epilepticus is 21%, with symptomatic epilepsy reflecting brain damage severity 2.
Early diagnosis and disorder-specific treatment are essential: Patients receiving targeted metabolic therapy have significantly better neurological outcomes than those treated only with standard antiepileptic drugs 6. Hypoglycemia from metabolic causes requires lifelong dietary management and emergency protocols to prevent recurrent episodes and progressive brain injury 3, 1.